TLK117 is primarily utilized in the field of cancer research and treatment, particularly in the development of targeted therapies. It functions as a proteasome inhibitor, which means it can disrupt the normal degradation of proteins within cancer cells, leading to their accumulation and subsequent cell death. This mechanism is especially effective in targeting malignant cells, as they rely heavily on the proteasome pathway for survival and proliferation. TLK117 is often studied for its potential to enhance the efficacy of chemotherapy and radiation therapy, making it a promising candidate for combination treatments. Additionally, its role in inducing apoptosis in cancer cells has garnered attention for its potential in overcoming drug resistance in certain types of cancers. Research is ongoing to explore its application in various cancer models, with a focus on improving therapeutic outcomes and reducing side effects.